Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 33

1.

MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.

Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN.

PLoS One. 2014 Sep 18;9(9):e107677. doi: 10.1371/journal.pone.0107677. eCollection 2014.

2.

Pain and Anxiety versus Sense of Family Support in Lung Cancer Patients.

Lekka D, Pachi A, Tselebis A, Zafeiropoulos G, Bratis D, Evmolpidi A, Ilias I, Karkanias A, Moussas G, Tzanakis N, Syrigos KN.

Pain Res Treat. 2014;2014:312941. doi: 10.1155/2014/312941. Epub 2014 Jul 13.

3.

Maintenance therapy with capecitabine in patients with locally advanced unresectable pancreatic adenocarcinoma.

Saif MW, Ledbetter L, Kaley K, Garcon MC, Rodriguez T, Syrigos KN.

Oncol Lett. 2014 Sep;8(3):1302-1306. Epub 2014 Jun 11.

4.

Mixed acinar-neuroendocrine carcinoma of the pancreas with neuroendocrine predominance.

Ogbonna OH, Garcon MC, Syrigos KN, Saif MW.

Case Rep Med. 2013;2013:705092. doi: 10.1155/2013/705092. Epub 2013 Nov 17.

5.

Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma.

Mohammad MM, Syrigos KN, Saif MW.

Case Rep Dermatol Med. 2013;2013:825717. doi: 10.1155/2013/825717. Epub 2013 Sep 1.

6.

Clinical importance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography in the management of patients with bronchoalveolar carcinoma: Role in the detection of recurrence.

Skoura E, Datseris IE, Exarhos D, Chatziioannou S, Oikonomopoulos G, Samartzis A, Giannopoulou C, Syrigos KN.

Oncol Lett. 2013 May;5(5):1687-1693. Epub 2013 Mar 14.

7.

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study.

Briasoulis E, Aravantinos G, Kouvatseas G, Pappas P, Biziota E, Sainis I, Makatsoris T, Varthalitis I, Xanthakis I, Vassias A, Klouvas G, Boukovinas I, Fountzilas G, Syrigos KN, Kalofonos H, Samantas E.

BMC Cancer. 2013 May 29;13:263. doi: 10.1186/1471-2407-13-263.

8.

Is there a role of targeted agents in the management of adrenocortical cancers?

Saif MW, Fallon B, Syrigos KN.

Case Rep Endocrinol. 2012;2012:875764. doi: 10.1155/2012/875764. Epub 2012 Nov 8.

9.

Desmoplasia in pancreatic cancer. Can we fight it?

Merika EE, Syrigos KN, Saif MW.

Gastroenterol Res Pract. 2012;2012:781765. doi: 10.1155/2012/781765. Epub 2012 Oct 22.

10.

Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer.

Dimou A, Syrigos KN, Saif MW.

Ther Adv Med Oncol. 2012 Sep;4(5):271-9. doi: 10.1177/1758834012446008.

11.

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

12.

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).

Kotoula V, Krikelis D, Karavasilis V, Koletsa T, Eleftheraki AG, Televantou D, Christodoulou C, Dimoudis S, Korantzis I, Pectasides D, Syrigos KN, Kosmidis PA, Fountzilas G.

BMC Cancer. 2012 Aug 6;12:342. doi: 10.1186/1471-2407-12-342.

13.

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis.

Pectasides D, Papaxoinis G, Kalogeras KT, Eleftheraki AG, Xanthakis I, Makatsoris T, Samantas E, Varthalitis I, Papakostas P, Nikitas N, Papandreou CN, Pentheroudakis G, Timotheadou E, Koutras A, Sgouros J, Bafaloukos D, Klouvas G, Economopoulos T, Syrigos KN, Fountzilas G.

BMC Cancer. 2012 Jun 29;12:271. doi: 10.1186/1471-2407-12-271.

14.

Bone lesions in recurrent glucagonoma: A case report and review of literature.

Ghetie C, Cornfeld D, Ramfidis VS, Syrigos KN, Saif MW.

World J Gastrointest Oncol. 2012 Jun 15;4(6):152-5. doi: 10.4251/wjgo.v4.i6.152.

15.

The Biological Role of PI3K Pathway in Lung Cancer.

Sarris EG, Saif MW, Syrigos KN.

Pharmaceuticals (Basel). 2012 Nov 20;5(11):1236-64. doi: 10.3390/ph5111236.

16.

Prolonged survival after splenectomy in Wiskott-Aldrich syndrome: a case report.

Syrigos KN, Makrilia N, Neidhart J, Moutsos M, Tsimpoukis S, Kiagia M, Saif MW.

Ital J Pediatr. 2011 Sep 10;37:42. doi: 10.1186/1824-7288-37-42.

17.

From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer.

Dimou A, Harrington K, Syrigos KN.

Patholog Res Int. 2011;2011:312346. doi: 10.4061/2011/312346. Epub 2011 Jul 18.

18.

The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series.

Saif MW, Kontny E, Syrigos KN, Shahrokni A.

J Oncol. 2011;2011:125467. doi: 10.1155/2011/125467. Epub 2011 Jun 13.

19.

Cerebrovascular accidents associated with sorafenib in hepatocellular carcinoma.

Saif MW, Isufi I, Peccerillo J, Syrigos KN.

Gastroenterol Res Pract. 2011;2011:616080. doi: 10.1155/2011/616080. Epub 2011 May 30.

20.

STAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.

Kotoula V, Lambaki S, Televantou D, Kalogera-Fountzila A, Nikolaou A, Markou K, Misailidou D, Syrigos KN, Fountzilas G.

Transl Oncol. 2011 Feb 1;4(1):47-58.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk